PATENT CLAIM ANALYSIS

Application Number: 16157007
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["514", "294000"]

Abstract:
Provided herein are pharmaceutical compositions comprising a vesicular monoamine transporter 2 (VMAT2) inhibitor (e.g., deutetrabenazine) and an excipient useful for treating stuttering in a subject in need thereof. Further provided are methods of treating stuttering in a subject in need thereof comprising administering an effective amount of a pharmaceutical composition of the present disclosure. Also provided herein are kits comprising such pharmaceutical compositions.

Claim (Index 20):
The kit of  claim 17 , wherein the one or more signs or symptoms of stuttering are selected from the group consisting of facial tics, lip tremors, excessive eye blinking, tension in the face, frustration when attempting to communicate, hesitation before beginning to speak, brief silence before uttering a word, pauses within a word, refusal to speak, interjections of an extra sound into a sentence, repetition of a sound, tension in the voice, rearrangement of words in a sentence, prolonging a word, prolonging sounds within a word, and difficulty starting a word.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 97.0
- Lexical Diversity: 1.61364
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15030271', '15116786', '15278192', '14735396', '13489516']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7728496200877172
- 35 USC 102 Novelty (BERT): 0.5066638260284129
- Combined Prediction Score: 0.7462310406817868
- Mean Citation Score: 174.34380800000002
- Max Citation Score: 213.72836
- Similarity Product: 125.5655720139575

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test